Antibody–Drug Conjugates (ADC) in HER2/neu-Positive Gynecologic Tumors
Molecules · 02.11.2023 · 28 (21) · 7389
DOI: 10.3390/molecules28217389 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Molecules, online erschienen am 02.11.2023. Verfasst von Blair McNamara und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, New Haven, CT 06520, USA. Hauptthemen laut MEDLINE: Immunoconjugates, Genital Neoplasms, Female, Antineoplastic Agents. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NCATS NIH HHS, NIH Research.
Abstract (Originalsprache)
Antibody–drug conjugates (ADCs) are a new class of targeted anti-cancer therapies that combine a monoclonal tumor-surface-receptor-targeting antibody with a highly cytotoxic molecule payload bonded through specifically designed cleavable or non-cleavable chemical linkers. One such tumor surface receptor is human epidermal growth factor 2 (HER2), which is of interest for the treatment of many gynecologic tumors. ADCs enable the targeted delivery of a variety of cytotoxic therapies to tumor cells while minimizing delivery to healthy tissues. This review summarizes the existing literature about HER2-targeting ADC therapies approved for use in gynecologic malignancies, relevant preclinical studies, strategies to address ADC resistance, and ongoing clinical trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, New Haven, CT 06520, USA.
ORCID-Profile: Blair McNamara, Michelle Greenman, Nicole Pebley, Levent Mutlu, Alessandro D Santin
Förderung
- NCI NIH HHS
- NCATS NIH HHS
- NIH Research
- Standup-to-Cancer (SU2C) Convergence
- Deborah Bunn Alley Foundation
- Domenic Cicchetti Foundation
- Discovery to Cure Foundation
- Guido Berlucchi Foundation
Zitieren
APA
McNamara, B., Greenman, M., Pebley, N., Mutlu, L., & Santin, A. D. (2023). Antibody–Drug Conjugates (ADC) in HER2/neu-Positive Gynecologic Tumors. Molecules, 28(21), 7389. https://doi.org/10.3390/molecules28217389
Vancouver
McNamara B, Greenman M, Pebley N, Mutlu L, Santin AD. Antibody–Drug Conjugates (ADC) in HER2/neu-Positive Gynecologic Tumors. Molecules. 2023;28(21):7389. doi:10.3390/molecules28217389
BibTeX
@article{McNamara2023,
author = {McNamara, Blair and Greenman, Michelle and Pebley, Nicole and Mutlu, Levent and Santin, Alessandro D},
title = {Antibody–Drug Conjugates (ADC) in HER2/neu-Positive Gynecologic Tumors},
journal = {Molecules},
year = {2023},
volume = {28},
number = {21},
pages = {7389},
doi = {10.3390/molecules28217389}
}
EUVIMED